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Background. Treatment for cutaneous leishmaniasis (CL) with standard pentavalent antimonial therapy is
hampered by cumbersome administration, toxicity, and potential failure. Knowledge of factors influencing treatment
outcome is essential for successful management.
Methods. A case-control study of incident cases was performed with patients experiencing their first CL episode.
The standard treatment for CL for these patients was 20 mg/kg/day of sodium stibogluconate for 20 days. Clinical
and epidemiological data were recorded, and parasite isolates were species typed. Patients were followed up for 6
months to assess treatment outcome. Clinical cure was defined as complete wound closure and re-epithelization
without inflammation or infiltration; new lesions, wound reopening, or signs of activity were classified as treatment
failure. Descriptive, bivariate, and logistic regression analyses were performed.
Results. One hundred twenty-seven patients were recruited; 63 (49.6%) were infected with Leishmania
(Viannia) peruviana, 29 (22.8%) were infected with Leishmania (Viannia) braziliensis, 27 (21.3%) were infected
with Leishmania (Viannia) guyanensis, and 8 (6.3%) were infected with other species. Only patients infected with
the 3 most common species were selected for risk-factor analysis ( ). Final failure rate at 6 months wasnp 119
24.4% (95% confidence interval [CI], 16.5%–32.1%), with 96% of failures occurring within the first 3 months of
follow-up assessment. Risk factors for treatment failure identified in the final multivariate model were age (per
year, odds ratio [OR], 0.95; 95% CI, 0.92–0.99; ), stay of !72 months in area of disease acquisition (OR,Pp .017
30.45; 95% CI, 2.38–389.25; ), duration of disease !5 weeks (OR, 4.39; 95% CI, 1.12–17.23; ),Pp .009 Pp .034
additional lesion (per lesion, OR, 2.06; 95% CI, 1.3–3.28; ), infection with L. (V.) peruviana (OR, 9.85;Pp .002
95% CI, 1.01–95.65; ), and infection with L. (V.) braziliensis (OR, 22.36; 95% CI, 1.89–263.96;Pp .049 Pp
)..014
Conclusions. The identification of parasite species and clinical risk factors for antimonial treatment failure
should lead to an improved management of CL in patients in Peru.
Cutaneous leishmaniasis (CL) is a vector-borne disease
caused by Leishmania species and poses increasing
health problems worldwide [1]. Outbreaks and incre-
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ments in its incidence have been associated with ur-
banization, travel, climatic change, and social conflict
in several regions of the world [2–10]. For the past 25
years, prevalence and incidence in the Americas have
been on the rise [11–13].
CL is a major health problem in Peru, with ∼6500
cases per year [14]. Seventy percent of the country has
endemic disease, which results in high morbidity, life-
long scarring, and cumbersome treatment to many al-
ready–resource-deprived communities. Leishmania
(Viannia) peruviana, Leishmania (Viannia) guyanensis,
and Leishmania (Viannia) braziliensis cause the major-
ity of cases [15]. This last species (i.e., L. [V.] brazil-
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iensis) is the principal etiological agent of mucosal leishmani-
asis, a chronic infiltrative disease of delayed onset that affects
the upper airways and, through factors yet unknown, appears
in 2%–3% of CL cases [6, 16–18].
Pentavalent antimonials are still considered, after nearly 50
years of use, first-line treatment for CL (either meglumine an-
timoniate or sodium stibogluconate [SSG]). Administration is
parenteral, for 20–30 days, with frequent adverse effects [19].
Several studies of antimonial therapy performed in Latin Amer-
ica show marked differences in cure rates, varying from 26.3%
to 100%, even within the same country [20–26]. Determinants
for this wide range can be due to host factors, parasite char-
acteristics, variable drug quality, concentration, or even study
design. Few studies have been conducted on the influence of
clinical, epidemiological, and host factors (i.e., immune re-
sponse and genetic background) on treatment outcome [27–
29]. Similarly, the effect of parasite species has been investigated
in a limited fashion [27, 30]. The in vitro models currently
used for measuring susceptibility to antimonials in parasite
isolates show wide variation and have no apparent relation to
actual clinical outcome after therapy [31, 32].
To investigate these issues, the Leishnatdrug-R consortium
was formed. Data dealing with the isolated effect of parasite
species and CL clinical outcome were published elsewhere [33].
In the present study, we increase our scope and aim to deter-
mine which clinical and epidemiological factors, after adjust-
ment by parasite species, play a role in treatment outcome for
CL. Using standard therapy and close patient follow-up, we
intend to build a risk-factor model that will serve as a useful
set of indicators for predicting antimonial treatment failure.
MATERIALS AND METHODS
Study population. We performed a prospective case-control
study of incident cases. The study took place between Novem-
ber 2001 and December 2004 at the Leishmaniasis Clinic lo-
cated in the Instituto de Medicina Tropical ”Alexander von
Humboldt,” Universidad Peruana Cayetano Heredia, in Lima,
Peru. The clinic serves patients from nearly all areas of endem-
icity in the country. Subjects from both sexes and all ages with
a first episode of parasitologically confirmed CL were recruited.
Those who completed treatment with SSG and had Leishmania
species typed were included in the final patient group. Patients
with mucosal involvement, who were pregnant or breast-feed-
ing, or who had major diseases were excluded. The study pro-
tocol and informed consent were approved by the Research
Ethics Committees of Universidad Peruana Cayetano Heredia
(Lima, Peru) and Institute of Tropical Medicine (Antwerp, Bel-
gium). Informed consent was obtained from all participating
subjects or their legal guardians.
Procedures. A clinical examination and epidemiological
questionnaire were completed at the time of recruitment. In-
formation included age, sex, main activity, region of disease
acquisition, duration of stay in an area of endemicity, and
duration of disease. Main activity was classified as low or high
risk of exposure to insect bites; high-risk activities included
agriculture, mining, and logging. Region of disease acquisition
was the geographic location where infection was acquired; en-
demic areas were grouped in 4 regions: 1 highland and 3 jungle
regions (northern, central, and southern). Duration of stay was
defined as the period of time spent in the region where infection
occurred, measured in months. Duration of disease was re-
corded as the time elapsed from when the patient first noticed
a lesion until therapy started, measured in weeks. Lesion de-
scription included number, diameter, type, location, and lymph
node involvement. Diameter was taken as the longest distance
between the edges of the biggest lesion, measured in centi-
meters. Types considered were ulcers, nonulcers (i.e., nodules
and plaques), and mixed forms.
Patients underwent leishmanin skin testing, prepared with
protein lysate from L. (V.) guyanensis LP52 strains (30 mg/mL).
A wheal 15 mm was considered positive, 48 h after inoculation
of 0.1 mL of lysate. Parasitological confirmation was done by
Giemsa-stained direct smear, culture of a lesion aspirate spec-
imen, or PCR. Culture samples were inoculated into Tobie
blood agar medium [34]. Qualitative PCR was done by min-
icircle kinetoplast DNA assay [35, 36]. For species identifica-
tion, multilocus PCR restriction-fragment–length polymor-
phism was performed, as described in a previous publication
from this study group [33].
Subjects received treatment on site, with standard supervised
daily administration of SSG following World Health Organi-
zation guidelines (20 mg Sb5+/kg/day for 20 days by intravenous
or intramuscular injection). Drugs were provided by 2 sources:
Albert-David, India (lot 3P12001), and Viteco, Colombia (lots
10700, 10800, 20600, 20700, and 30600). Quality control for
Sb5+ concentration in all batches was performed by the Inter-
national Dispensary Association (Amsterdam, The Nether-
lands). Lesion progression was monitored during treatment.
Follow-up visits were scheduled for 1, 2, 3, 6, and 12 months
after treatment ended. At each visit, patients were classified
clinically for 2 possible outcomes: (1) cure, defined as complete
wound healing, with epithelization and absence of any sign of
activity or inflammation; and (2) failure, increased inflam-
mation around the initial lesion, with or without epithelization,
clinical regression of a healed lesion, or presence of new le-
sion(s) or a satellite lesion around the initial one.
Lesions in the process of closure were considered to be pend-
ing until they reached 1 of the 2 final outcomes. The treatment
was considered to be a failure if lesions remained at 6-month
follow up. Once treatment failure was determined, follow-up
assessment stopped, and second-line treatment was adminis-
tered. Cured patients were still observed until 12 months to
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Figure 1. Kaplan-Meyer survival curve showing clinical failures detected during follow-up visits in Peruvian patients with cutaneous leishmaniasis
( ).np 119
detect possible relapses, defined as reappearance of active in-
fection after cure was achieved. In the case of multiple lesions,
clinical outcome was defined by the status of the least well-
healed lesion.
Statistical analysis. Statistical analysis was performed us-
ing EpiInfo, version 3.3.2 (Centers for Disease Control and
Prevention), and NCSS Statistical Software, version 2006
(Number Cruncher Statistical Systems). Frequencies and pro-
portions were used to describe categorical variables. Means,
medians, and SDs were obtained for numeric variables. Dis-
tributions of continuous variables were further analyzed; those
without normal distribution were stratified using quartiles.
Kaplan-Meier survival curves were obtained to assess failure
rates over time; pending and cure cases were grouped together.
Variables were grouped according to clinical outcome at the
sixth month, considered the final end point, because no more
pending cases remained. Pearson’s x2 test was used for cate-
gorical variable comparison, and Mann-Whitney U and Krus-
kal-Wallis tests were used for nonnormal numeric variables.
ORs were calculated for variables with significance levels.10,
by simple logistic regression. These risk factors were then in-
troduced in order of significance into a multivariate model and
were tested by means of multiple logistic regression and re-
ceiver-operating-characteristic (ROC) curves. Possible inter-
actions between variables were analyzed. Confounders and risk
factors that lost significance were excluded from the final
model. Significance was set at .P ! .05
RESULTS
Species typing. A total of 127 patients met the selection cri-
teria. The 3 most common species identified were L. (V.) pe-
ruviana, L. (V.) braziliensis, and L. (V.) guyanensis, with 63
samples (49.6%), 29 samples (22.8%), and 27 samples (21.3%),
respectively. The remaining isolates were typed as L. (V.) lain-
soni ( ), L. (L.) mexicana ( ), and a L. (V.) peruviana/np 6 np 1
braziliensis hybrid ( ). L. (V.) peruviana was the most com-np 1
mon species in the Andean highlands (88.5%). The jungle
regions showed a diverse distribution: L. (V.) guyanensis was
more common in the central jungle (57.1%), whereas L. (V.)
braziliensis predominated in the southern jungle (64.7%). There
was significant association ( , by x2 test) between speciesP ! .001
and geographical region.
Outcome end points. Patients with the 3 most common
species were selected for outcome comparison ( ). Eachnp 119
had at least 1 follow-up visit during the first 3 months and 1
visit after 6 months. A total of 29 patients (24.4%; 95% CI,
16.5%–32.1%) had treatment failure at some point in the fol-
low-up period. The survival curve (figure 1) shows that the
majority of treatment failures occurred within the first 3
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Figure 2. Kaplan-Meyer survival curve showing clinical failures detected during follow-up visits, stratified by the 3 main species analyzed (np
). Solid line, Leishmania (Viannia) guyanensis; dotted line, Leishmania (Viannia) peruviana; dashed line, Leishmania (Viannia) braziliensis.119
months after therapy finished: at 1 month, 54% of failures had
already occurred; at 2 months, 81% had occurred; and at 3
months, 94.6% of failures had occurred.
Failure rates at 6 months were 7.4% (95% CI, 2.3%–23.5%)
for L. (V.) guyanensis, 28.6% (95% CI, 18.9%–40.7%) for L.
(V.) peruviana, and 31.0% (95% CI, 17.3%–49.4%) for L. (V.)
braziliensis (figure 2). Pair-by-pair comparisons were per-
formed; L. (V.) guyanensis was associated with a significantly
lower clinical failure than was L. (V.) peruviana ( ) orPp .037
L. (V.) braziliensis ( ). The difference in clinical out-Pp .026
come between L. (V.) peruviana and L. (V.) braziliensis was not
significant.
Description of patient characteristics by treatment outcome.
Demographic, epidemiological, and clinical characteristics, cat-
egorized by the 2 clinical outcomes, are shown and statistically
compared in table 1. Patients whose treatment failed were sig-
nificantly younger than cured patients (16.0 vs. 31.2 years) and
were more likely to have stayed !72 months (75th percentile)
in the disease-transmission area. High-risk activities were more
common among cured patients, although the difference was
not significant. Sex and region of disease acquisition were not
found to be associated with clinical outcome. Infection treated
early (!5 weeks after onset; 25th percentile) and multiple lesions
were significantly more common in patients whose treatment
failed. There was a trend toward smaller lesion diameter and
absence of enlarged lymph nodes in patients with clinical fail-
ures. Lesion location showed no statistical difference, with sim-
ilar distributions between groups.
Detection rates were 88.2% for direct smear and 81.5% for
culture. There was no statistical difference between cure and
failure groups in either test ( and , re-Pp .349 Pp .367
spectively).
Bivariate and multivariate risk-factor analysis. Risk fac-
tors for treatment failure in the final multivariate model were
age, duration of stay in the region where disease was acquired,
duration of disease, number of lesions, and parasite species
(table 2).
Four variables with significance in the bivariate analysis were
excluded from the multivariate model because of interactions.
High-exposure occupations depended strongly on age (P !
, by Student t test), because children (from infants to school.001
students) were classified as part of the low-risk activity group.
Species type influenced lesion presentation; nonulcerative or
mixed lesions occurred more frequently with L. (V.) peruviana
infection ( , by x2 test). The presence of enlarged lymphPp .067
nodes was found to depend on lesion diameter ( , byPp .013
Mann-Whitney U test), and this parameter, in turn, was influ-
enced by 2 other factors: duration of disease ( , byPp .073
Table 1. Demographic, epidemiological, and clinical characteristics of cutaneous leish-
maniasis–affected patients and cure and failure outcome after antimonial treatment.
Factor
Treatment outcome at 6 months
P a
Failure
(n p 29)
Cure
(n p 90)
Age, years
Mean  SD 16.04  13.6 31.17  20.5
Median (IQR) 12 (7–21) 25.5 (22–33) .001b
Sex
Male 17 (58.6) 56 (62.2) .729
Female 12 (41.4) 34 (37.8)
Main activity
High risk 9 (31.0) 44 (48.9) .092
Low risk 20 (69.0) 46 (51.1)
Region of acquisition
Western Andes 14 (48.3) 45 (50.0) .464
North Jungle 3 (10.3) 10 (11.1)
Central Jungle 6 (20.7) 26 (28.9)
South Jungle 6 (20.7) 9 (10.0)
Duration of stay in area of endemicity, months
Mean  SD 18.22  32.6 113.24  215.4
Median (IQR) 3 (1–5) 6 (3–12) .081b
0–72 28 (96.6) 31 (69.3) .003
172 1 (3.4) 27 (30.7)
Duration of disease, weeks
Mean  SD 11.87  8.7 14.80  11.4
Median (IQR) 11 (6.6–13.1) 12.4 (8.9–13.7) .169b
0–5 8 (27.6) 9 (10.0) .019
15 21 (72.4) 81 (90.0)
Lesions, no.
Mean  SD 2.44  1.7 1.73  1.2
Median (IQR) 2 (1–3) 1 (1–2) .018b
Lesion diameter, cm
Mean  SD 1.80  1.2 2.48  1.7
Median (IQR) 1.4 (1–2.3) 2 (1.9–2.5) .075b
Lesion type
Ulcer 19 (65.5) 70 (77.8) .170
Nonulcer 1 (3.4) 6 (6.7)
Mixed 9 (31.0) 14 (15.6)
Lesion location
Face 8 (27.6) 23 (25.6) .892
Upper extremities 6 (20.7) 24 (26.7)
Lower extremities 7 (24.1) 24 (26.7)
Trunk 1 (3.4) 4 (4.4)
Multiple 7 (24.1) 15 (16.7)
Regional lymph nodes
Yes 4 (13.8) 26 (28.9) .103
No 25 (86.2) 64 (71.1)
Leishmanin skin test, result
Positive 22 (91.7) 79 (92.9) .833
Negative 2 (8.3) 6 (7.1)
NOTE. Data are no. (%) of case patients, unless otherwise indicated. Pearson’s x2 test was performed
on all discrete variables. IQR, interquartile range.
a .a ! .05
b Determined by Mann-Whitney U test.
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Table 2. Bivariate and multivariate analysis of risk factors for treatment failure in patients with
cutaneous leishmaniasis.
Factor
Bivariate analysis Multivariate analysisa
OR (95% CI) P b OR (95% CI) P b
Age (in years), per each additional year 0.95 (0.92–0.98) .001 0.95 (0.92–00.99) .017
High-risk main activity 0.47 (0.19–1.14) .096 …
Duration of stay, 72 months 12.39 (1.60–96.1) .016 30.45 (2.38–389.25) .009
Duration of disease, 5 weeks 3.43 (1.18–9.96) .024 4.39 (1.12–17.23) .034
No. of lesions, per each additional lesion 1.42 (1.06–1.89) .017 2.06 (1.30–3.28) .002
Lesion diameter, per each additional cm, cm 0.69 (0.48–1.00) .052 …
Lesion type
Ulcer 1.00 …
Nonulcer 0.61 (0.07–5.41) .661 …
Affected lymph node 0.39 (0.12–1.24) .112 …
Species
Leishmania (Viannia) guyanensis 1.00 …
Leishmania (Viannia) peruviana 5.00 (1.07–23.3) .040 9.85 (1.01–95.65) .049
Leishmania (Viannia) braziliensis 5.63 (1.09–28.99) .039 22.36 (1.89–263.96) .014
NOTE. Eligible factors for entrance into the logistic regression model had .P ! .10
a The final model included 117 patients. Adjustment score, 31; likelihood ratio, 42.97; .P ! .001
b .a ! .05
Mann-Whitney U test) and species type, because larger lesions
were more common with L. (V.) guyanensis infection (Pp
, by Kruskal-Wallis test)..058
DISCUSSION
This study found an overall treatment-failure rate of 24.4% for
CL-affected patients after a first course of SSG treatment, con-
sistent with past findings in Peru [37, 38]. Only treatment-
naive, first-infection patients were included in the study, to
control for biases and confounders related to clinical and out-
come differences after treatment failure. The majority of treat-
ment failures occurred within the first 3 months after treatment
finished (figure 1), as described elsewhere [27]. It can be safely
assumed that, by the third month, the full effect of therapy
would have already been observed. Cures occurring after this
period are more likely to be related to spontaneous cure than
to a delayed effect of therapy [39].
Among the risk factors found, young age was the most solid
predictor of treatment failure. Previous studies also report this
finding, even linking failure to pediatric population [27–29].
Although there is not yet a clear explanation, possible differ-
ences in child immune response, drug pharmacokinetics, and
exposure to antigens may affect outcome. Impaired cellular and
acquired immunity due to immune-system immaturity may
determine poor parasite clearance and prolonged infection. Dif-
ferences such as cytokine profile, Th1/Th2 T cell polarity, and
macrophage function between children and adults have been
documented in tuberculosis and other parasitic infections [40–
42]. Different pharmacokinetics may also explain poor treat-
ment response, suggesting the need for dose adjustment, be-
cause children achieve lower peak concentrations and have
higher clearance [28, 43]. It has also been suggested that poor
response in children could be related to short exposure to par-
asite antigens and sand fly saliva [44]. In this study, most of
the age effect was found to be independent of duration of stay,
suggesting a direct role. Regardless of the explanation, it is clear
that children are at greater risk of treatment failure and warrant
close supervision during therapy.
Duration of stay was a second important factor influencing
outcome. Evidence shows that protective immunity increases
with permanence. Long-time dwellers are chronically exposed
to vector saliva and subclinical parasite inoculations, which may
influence immune system preparedness for a full-scale infection
[44]. Visitors lacking this long-term exposure find themselves
acutely exposed, with an immune system prone to fail in
mounting an adequate response [9]. Furthermore, healthy in-
dividuals with positive skin test results or past infections are
less susceptible to secondary infection [37]. The present study
found that it takes 6 years in an area of endemicity to achieve
protection. In practice, this slow process will benefit only long-
term residents. An indirect measure of exposure to sand fly
bites is the frequency of outdoor activities, yet evidence for its
role is contradictory [45–47]. In this case, high-exposure ac-
tivities were not a significant factor influencing treatment
outcome.
Another important determinant for treatment failure was
disease duration. In contrast to many infectious diseases, early
treatment in CL apparently is not beneficial. Prompt diagnosis
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and management within 5 weeks of infection significantly in-
creased failure rate, to 47%. A previous study reported a similar
failure rate of 46% in patients with !20 days of disease [48].
Intervention before reaching an effective acquired immunity is
the likely explanation of this phenomenon. The initial response
to infection was shown to be nonspecific and not fully directed
toward parasite elimination [48]. A 2-phase mouse model of
infection has been reported. The initial phase, which lasted 4–
5 weeks, favored parasite amplification in the dermis without
lesion formation. In the second phase, lesions appeared con-
currently with inflammatory cell infiltration and IFN-g in-
crease, giving way to parasite clearance [49]. Human tissue with
early disease (!8 weeks) had high IL-10 and low IFN-g con-
centrations. As lesions progressed, the IFN-g level increased,
whereas the IL-10 level decreased [50]. It is possible that reg-
ulatory T cells play a major role in this process, because they
suppress T cell effector response through IL-10 [51]. They block
parasite eradication from the tissue to ensure protective im-
munity to reinfection [52–55]. In summary, evidence suggests
that treatment during the early phase of illness may be unsuc-
cessful because of inadequate effector response. Additional
studies are needed to determine whether delaying therapy is a
warranted measure for early CL.
Failure rate increases with each additional lesion, as seen in
other studies [27, 29, 37]. An increased number of lesions may
imply greater parasite load, which impairs clearance. An alter-
native explanation is that each lesion corresponds to different
sand fly bites, which leads to the coexistence of several parasite
clones with dissimilar susceptibility profiles. Although bivariate
analysis showed an increased risk with small lesions (!5 mm),
this association lost significance in the multivariate model, be-
cause of interaction with duration of disease. The lack of re-
sponse in small and mixed lesions is probably due to their early
nature, as previously discussed.
Several studies have shown the influence of parasite species
on clinical outcome after antimonial treatment. L. (V.) brazil-
iensis had lower failure rates than did L. (V.) guyanensis and L.
mexicana in Brazil and Guatemala, respectively [27, 30]. In
contrast, the present study found that treatment of L. (V.)
guyanensis had a lower failure rate than for either L. (V.) bra-
ziliensis or L. (V.) peruviana. Apart from study-design differ-
ences, it is possible to explain the disparities by considering
the existence of genetic variations within individual species. A
considerable intraspecific polymorphism has been documented
for L. (V.) braziliensis and L. (V.) guyanensis [56–58]. In ad-
dition, 2 distinct genotypes of L. (V.) guyanensis have been
linked to different clinical presentations and ecological regions
[59]. The same phenomenon may exist in Peru and Brazil.
Natural tolerance of the parasite to antimonials could influ-
ence treatment outcome. In vitro studies have shown varying
intrinsic susceptibility among species [32]. Nevertheless, a re-
cent study did not find any correlation between treatment out-
come and natural tolerance to antimonials in L. (V.) braziliensis
and L. (V.) guyanensis strains [31]. This discrepancy may reflect
the inadequacy of the in vitro amastigote-macrophage model
to assess chemotherapy outcome in the patient. It is possible
that each species produces a particular immune response that,
combined with the host’s genetic background, could ultimately
influence clinical outcome [60, 61].
Exact species identification is still an elaborate process and
is not performed routinely. Data from past Peruvian surveys
could provide a practical solution by linking the region of dis-
ease acquisition to a predominant parasite species [15, 33].
Nevertheless, this approach may not be sufficient when current
changes in worldwide transmission cycles are considered [62].
Particular efforts should be undertaken to increase accessibility
and to simplify molecular assays for species identification. Sev-
eral approaches are promising: (1) loop-mediated isothermal
amplification, which needs a simple water bath; and (2) PCR-
oligochromatography, which allows visualization after 5 min
on a dipstick, via hybridization with a gold-conjugated probe
[63, 64].
In conclusion, young patients with short stays in areas of
endemicity, !5 weeks of disease, multiple lesions, and L. (V.)
braziliensis infection are at the highest risk of experiencing fail-
ure of SSG therapy. This risk-factor model can be explained
by 4 key determinants: (1) incipient immune response (young
age and early disease), (2) short exposure to parasites and vector
bites (duration of stay), (3) higher parasite load (number of
lesions), and (4) the inherent characteristics of the individual
Leishmania species.
Precise knowledge of the clinical and epidemiological be-
havior, treatment evolution, and healing process in leishman-
iasis is of utmost importance for improving public health pol-
icies. A risk-factor approach, including predominant pathogen
species, is essential for optimal clinical management of CL and
would make the burden of disease more bearable; ultimately,
development of more efficacious, safe, and practical drugs for
the treatment of CL is urgently needed.
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